# Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)

> **NCT05396885** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Kite, A Gilead Company** · enrollment: 136 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **BIOLOGICAL:** anitocabtagene-autoleucel

## Key facts

- **NCT ID:** NCT05396885
- **Lead sponsor:** Kite, A Gilead Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-07-15
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 136 (ACTUAL)
- **Last updated:** 2026-02-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05396885

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05396885, "Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05396885. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*